-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, stocks in the pharmaceutical sector have skyrocketed.
Taking China Pharmaceuticals as an example, it has achieved 11 daily limits in the past 14 trading days
.
Analysts pointed out that it is not only Chinese medicine that has performed well recently.
The stock prices of pharmaceutical companies such as Chengda Pharmaceutical, Hongri Pharmaceutical, Zhongsheng Pharmaceutical, Essence Pharmaceutical, and Fosun Pharmaceutical also have several daily limits
.
Among them, according to exchange market data, on March 21, China Pharmaceutical closed the 11th daily limit in recent years
.
The closing share price was reported at 36.
59 yuan, an increase of 10.
01%
.
Since March, Sinopharm has risen from 11.
01 yuan to 36.
59 yuan, a cumulative increase of 232.
33%, and the company's total market value has increased by 27.
332 billion yuan.
According to the latest number of shareholders of 86,397, from March 1 to March 21, the company's shareholders The per capita net income is 316,300 yuan
.
However, on the evening of March 21, China Pharmaceutical issued a risk warning announcement saying, "Since March 2, 2022, the company's stock price has increased by nearly 230%, and it has encountered abnormal fluctuations in stock trading five times
.
As of March 2022 On the closing day of the 21st, after consulting Wind information, the median price-earnings ratio (TTM) of the pharmaceutical circulation industry was 16.
86, and the company's price-earnings ratio (TTM) was 43.
05, which was significantly higher than the price-earnings ratio of the same industry.
The impact of the company's performance, there are irrational investment situations, investors are advised to pay attention to investment risks, make rational decisions, and invest prudently
.
" It is reported that this is the fourth risk warning announcement issued by Sinopharm since March.
On March 5, March 13 and March 17, the company also issued risk warning announcements respectively
.
According to the industry, investment opportunities in the pharmaceutical sector are greater than investment risks
.
For example, according to the 2021 performance forecast released by the company recently, nearly 80% of pharmaceutical companies are profitable
.
From the perspective of net profit, the net profit of multi-pharmaceutical companies has increased by more than 10 times
.
For example, Jimin Medical’s 2021 performance report shows that in 2021, Jimin Medical’s operating income will increase by 26% year-on-year to 1.
1 billion yuan; achieved a 22-fold increase
.
In 2021, Rejing Bio’s operating income will increase by 9 times year-on-year to 5.
37 billion yuan; the net profit attributable to the parent will increase by 18 times year-on-year to 2.
19 billion yuan
.
Lisheng Pharmaceutical will achieve an operating income of 1.
09 billion yuan in 2021, a year-on-year decrease of 4.
29%; but its net profit will reach 137 million yuan, a year-on-year increase of 1312%, or a 13-fold increase
.
As for the growth in performance, analysts pointed out that Thermal View Bio mainly benefits from detection reagents, and reagent detection is still a scarce resource in the market, which should be able to support the development of the company's stock to higher prices
.
But for Jimin Medical, analysts said that the company's net profit growth, about 300 million yuan is non-recurring profit and loss, the profit is more water, from a long-term point of view, its real performance is difficult to support the long-term rise of the stock , investors need to be cautious
.
Lisheng Pharmaceutical stated that in the face of the impact of the epidemic and industry changes, the company actively took effective measures to strengthen budget management and cost control, and compressed various controllable expenses.
In 2021, both sales and administrative expenses dropped significantly
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
Taking China Pharmaceuticals as an example, it has achieved 11 daily limits in the past 14 trading days
.
Analysts pointed out that it is not only Chinese medicine that has performed well recently.
The stock prices of pharmaceutical companies such as Chengda Pharmaceutical, Hongri Pharmaceutical, Zhongsheng Pharmaceutical, Essence Pharmaceutical, and Fosun Pharmaceutical also have several daily limits
.
Among them, according to exchange market data, on March 21, China Pharmaceutical closed the 11th daily limit in recent years
.
The closing share price was reported at 36.
59 yuan, an increase of 10.
01%
.
Since March, Sinopharm has risen from 11.
01 yuan to 36.
59 yuan, a cumulative increase of 232.
33%, and the company's total market value has increased by 27.
332 billion yuan.
According to the latest number of shareholders of 86,397, from March 1 to March 21, the company's shareholders The per capita net income is 316,300 yuan
.
However, on the evening of March 21, China Pharmaceutical issued a risk warning announcement saying, "Since March 2, 2022, the company's stock price has increased by nearly 230%, and it has encountered abnormal fluctuations in stock trading five times
.
As of March 2022 On the closing day of the 21st, after consulting Wind information, the median price-earnings ratio (TTM) of the pharmaceutical circulation industry was 16.
86, and the company's price-earnings ratio (TTM) was 43.
05, which was significantly higher than the price-earnings ratio of the same industry.
The impact of the company's performance, there are irrational investment situations, investors are advised to pay attention to investment risks, make rational decisions, and invest prudently
.
" It is reported that this is the fourth risk warning announcement issued by Sinopharm since March.
On March 5, March 13 and March 17, the company also issued risk warning announcements respectively
.
According to the industry, investment opportunities in the pharmaceutical sector are greater than investment risks
.
For example, according to the 2021 performance forecast released by the company recently, nearly 80% of pharmaceutical companies are profitable
.
From the perspective of net profit, the net profit of multi-pharmaceutical companies has increased by more than 10 times
.
For example, Jimin Medical’s 2021 performance report shows that in 2021, Jimin Medical’s operating income will increase by 26% year-on-year to 1.
1 billion yuan; achieved a 22-fold increase
.
In 2021, Rejing Bio’s operating income will increase by 9 times year-on-year to 5.
37 billion yuan; the net profit attributable to the parent will increase by 18 times year-on-year to 2.
19 billion yuan
.
Lisheng Pharmaceutical will achieve an operating income of 1.
09 billion yuan in 2021, a year-on-year decrease of 4.
29%; but its net profit will reach 137 million yuan, a year-on-year increase of 1312%, or a 13-fold increase
.
As for the growth in performance, analysts pointed out that Thermal View Bio mainly benefits from detection reagents, and reagent detection is still a scarce resource in the market, which should be able to support the development of the company's stock to higher prices
.
But for Jimin Medical, analysts said that the company's net profit growth, about 300 million yuan is non-recurring profit and loss, the profit is more water, from a long-term point of view, its real performance is difficult to support the long-term rise of the stock , investors need to be cautious
.
Lisheng Pharmaceutical stated that in the face of the impact of the epidemic and industry changes, the company actively took effective measures to strengthen budget management and cost control, and compressed various controllable expenses.
In 2021, both sales and administrative expenses dropped significantly
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
